4
Changes in Ownership
Allogene Therapeutics, Inc. Filed Acc 0001209191-19-043755
Chief Technical Officer sold 48,827 shares at an average $29.44 ($1,437,603)
- Chief Technical Officer acquired 48,827 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| MOORE ALISON Chief Technical Officer | 2019-07-26 | Option exercise | +13,193 | $2.27 | $29,948 | 78,566 | D: show line 1 in the form |
| MOORE ALISON Chief Technical Officer | 2019-07-26 | Sale | −13,193 | $29.18 | $384,994 | 65,373 | D: show line 2 in the form |
| MOORE ALISON Chief Technical Officer | 2019-07-29 | Option exercise | +23,815 | $2.27 | $54,060 | 89,188 | D: show line 3 in the form |
| MOORE ALISON Chief Technical Officer | 2019-07-29 | Sale | −23,815 | $29.39 | $699,870 | 65,373 | D: show line 4 in the form |
| MOORE ALISON Chief Technical Officer | 2019-07-30 | Option exercise | +11,819 | $2.27 | $26,829 | 77,192 | D: show line 5 in the form |
| MOORE ALISON Chief Technical Officer | 2019-07-30 | Sale | −11,819 | $29.85 | $352,738 | 65,373 | D: show line 6 in the form |
| Open-market sales · 48,827 sh · avg $29.44 · $1,437,603 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| MOORE ALISON Chief Technical Officer | 2019-07-26 | Option exercise · Stock Option (Right to Buy) | −13,193 | 802,663 | D: show line 7 in the form | ||
| MOORE ALISON Chief Technical Officer | 2019-07-29 | Option exercise · Stock Option (Right to Buy) | −23,815 | 778,848 | D: show line 8 in the form | ||
| MOORE ALISON Chief Technical Officer | 2019-07-30 | Option exercise · Stock Option (Right to Buy) | −11,819 | 767,029 | D: show line 9 in the form |
Loading xslF345X03/doc4.xml…